Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of a malaria vaccine, Ad35.CS.01, and how
the body reacts to vaccination. Participants will include 48 Berkinabè healthy males and
females ages 18-45 years in Burkina Faso. Volunteers for this study will be divided into 4
groups. Members of each group (12 per group) will receive an increasing dose of vaccine or
placebo (an inactive substance). Ten will receive the malaria vaccine and 2 will receive
placebo. Study procedures include: physical exam, urine sample, and blood samples.
Participants will be involved in study related procedures for about 13 months.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)